NM_032826.5(SLC35B4):c.483A>T (p.Leu161Phe) AND not specified

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Mar 15, 2024
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV004672585.1

Allele description [Variation Report for NM_032826.5(SLC35B4):c.483A>T (p.Leu161Phe)]

NM_032826.5(SLC35B4):c.483A>T (p.Leu161Phe)

Gene:

SLC35B4:solute carrier family 35 member B4 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

7q33

Genomic location:

Preferred name:

NM_032826.5(SLC35B4):c.483A>T (p.Leu161Phe)

HGVS:

NC_000007.14:g.134301765T>A
NM_032826.5:c.483A>TMANE SELECT
NP_116215.1:p.Leu161Phe
NC_000007.13:g.133986517T>A
NM_032826.4:c.483A>T

Protein change:

L161F

Molecular consequence:

NM_032826.5:c.483A>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:: AllHighlyPenetrant
Identifiers:: MedGen: CN169374

Recent activity

Clear Turn Off Turn On

diacylglycerol kinase eta isoform X4 [Rattus norvegicus]
diacylglycerol kinase eta isoform X4 [Rattus norvegicus]
gi|1958682399|ref|XP_038949966.1|

Protein
RecName: Full=Tryptophan 2,3-dioxygenase; Short=TDO; AltName: Full=Protein vermi...
RecName: Full=Tryptophan 2,3-dioxygenase; Short=TDO; AltName: Full=Protein vermilion; AltName: Full=Tryptamin 2,3-dioxygenase; AltName: Full=Tryptophan oxygenase; Short=TO; Short=TRPO; AltName: Full=Tryptophan pyrrolase; AltName: Full=Tryptophanase
gi|221222799|sp|B4JKK1.1|T23O_DROGR

Protein
t(1;22)
t(1;22)

MedGen
BRCA2 Biallelic Inactivation
BRCA2 Biallelic Inactivation

MedGen
t(1;7)(p33;q35)
t(1;7)(p33;q35)

MedGen

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV005166847	Ambry Genetics	criteria provided, single submitter (Ambry Variant Classification Scheme 2023)	Uncertain significance (Mar 15, 2024)	germline	clinical testing	Citation Link

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV005166847

Ambry Genetics

criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)

Uncertain significance
(Mar 15, 2024)

germline

clinical testing

Citation Link

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Details of each submission

From Ambry Genetics, SCV005166847.1

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	not provided

Description

The c.483A>T (p.L161F) alteration is located in exon 6 (coding exon 6) of the SLC35B4 gene. This alteration results from a A to T substitution at nucleotide position 483, causing the leucine (L) at amino acid position 161 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Aug 11, 2024

ClinVar

Relating variation to medicine